Q2 2024 Personalis Inc Earnings Call Transcript
Key Points
- Personalis Inc (PSNL) achieved a 35% year-over-year revenue growth, reaching $22.6 million in Q2 2024.
- Biopharma business grew 117% year-over-year, driven by strong demand for tumor profiling and MRD products.
- Gross margin expanded to 35.6%, up from 28.7% in the same period last year, due to product cost reduction and operating leverage.
- Personalis Inc (PSNL) increased its full-year revenue guidance to $79-$81 million, up from the previous $76-$78 million.
- The company has a strong balance sheet with $87 million in cash and short-term investments, expected to last through Q1 2026.
- Operating expenses were $24.9 million, though reduced from $30.1 million in the prior year, still represent a significant cost.
- Net loss for Q2 2024 was $12.8 million, although an improvement from $24 million in the prior year, it remains a substantial deficit.
- The company faces risks and uncertainties that could cause actual results to differ materially from current expectations.
- Personalis Inc (PSNL) is still awaiting Medicare reimbursement for its NeXT Personnel test, which could impact future revenue.
- The company’s enterprise relationship with Natera is expected to wind down by the end of 2024, potentially affecting future revenue streams.
Good day and welcome to the Personalis second-quarter 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Mr. Caroline Corner, Investor Relations. Please go ahead.
Thank you, operator. Welcome to Personalisâ second-quarter 2024 earnings call. Joining todayâs call are Chris Hall, Chief Executive Officer and President; Aaron Tachibana, Chief Financial and Chief Operating Officer; and Rich Chen, Chief Medical Officer and EVP, R&D.
All statements made on this call that do not relate to matters of historical facts should be considered forward-looking statements within the meaning of U.S. securities laws. For example, any statements regarding trends and expectations for our financial performance this year and longer term, cash runway, revenue expectations and timing, reimbursement goals, size and booking of orders, products, services, technology, clinical milestones, the outcome and timing of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
